GU Cancers 2020 | First-line therapy options in mRCC

Hans Hammers

Hans Hammers, MD, PhD, The University of Texas Southwestern, Dallas, TX, discusses how healthcare professionals come to a decision about the appropriate first-line targeted therapy in metastatic renal cell carcinoma (mRCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter